View in EDS HTML Full Text PDF Full Text

The MIF-CD74 axis drives colorectal cancer via glycolytic reprogramming and is targeted by a novel small-molecule inhibitor.

Saved in:
Bibliographic Details
Title: The MIF-CD74 axis drives colorectal cancer via glycolytic reprogramming and is targeted by a novel small-molecule inhibitor.
Authors: Lou J; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China.; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China., Chen Y; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China.; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China., Li Y; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China., Liu Z; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China., Hu S; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.; School of Medicine, Southeast University, Nanjing, Jiangsu, 210009, China., Ding M; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China.; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China., Qin J; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China., Sun H; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China. sunhuiling1988@yeah.net.; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China. sunhuiling1988@yeah.net.; Jiangsu Collaborative Innovation Center on Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, 211100, China. sunhuiling1988@yeah.net., Pan Y; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China. panyuqin@njmu.edu.cn.; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China. panyuqin@njmu.edu.cn.; Jiangsu Collaborative Innovation Center on Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, 211100, China. panyuqin@njmu.edu.cn.
Source: Cellular oncology (Dordrecht, Netherlands) [Cell Oncol (Dordr)] 2026 Apr 22; Vol. 49 (3). Date of Electronic Publication: 2026 Apr 22.
Publication Type: Journal Article
Journal Info: Publisher: Springer Country of Publication: Netherlands NLM ID: 101552938 Publication Model: Electronic Cited Medium: Internet ISSN: 2211-3436 (Electronic) Linking ISSN: 22113428 NLM ISO Abbreviation: Cell Oncol (Dordr) Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42018204
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The MIF-CD74 axis drives colorectal cancer via glycolytic reprogramming and is targeted by a novel small-molecule inhibitor.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Lou+J%22">Lou J</searchLink>; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China.; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.<br /><searchLink fieldCode="AU" term="%22Chen+Y%22">Chen Y</searchLink>; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China.; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.<br /><searchLink fieldCode="AU" term="%22Li+Y%22">Li Y</searchLink>; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China.<br /><searchLink fieldCode="AU" term="%22Liu+Z%22">Liu Z</searchLink>; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China.<br /><searchLink fieldCode="AU" term="%22Hu+S%22">Hu S</searchLink>; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.; School of Medicine, Southeast University, Nanjing, Jiangsu, 210009, China.<br /><searchLink fieldCode="AU" term="%22Ding+M%22">Ding M</searchLink>; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China.; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.<br /><searchLink fieldCode="AU" term="%22Qin+J%22">Qin J</searchLink>; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.<br /><searchLink fieldCode="AU" term="%22Sun+H%22">Sun H</searchLink>; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China. sunhuiling1988@yeah.net.; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China. sunhuiling1988@yeah.net.; Jiangsu Collaborative Innovation Center on Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, 211100, China. sunhuiling1988@yeah.net.<br /><searchLink fieldCode="AU" term="%22Pan+Y%22">Pan Y</searchLink>; General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China. panyuqin@njmu.edu.cn.; General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China. panyuqin@njmu.edu.cn.; Jiangsu Collaborative Innovation Center on Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, 211100, China. panyuqin@njmu.edu.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101552938%22">Cellular oncology (Dordrecht, Netherlands)</searchLink> [Cell Oncol (Dordr)] 2026 Apr 22; Vol. 49 (3). <i>Date of Electronic Publication: </i>2026 Apr 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>101552938 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2211-3436 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2222113428%22">22113428 </searchLink><i>NLM ISO Abbreviation: </i>Cell Oncol (Dordr) <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42018204
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s13402-026-01202-9
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: The MIF-CD74 axis drives colorectal cancer via glycolytic reprogramming and is targeted by a novel small-molecule inhibitor.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lou J
      – PersonEntity:
          Name:
            NameFull: Chen Y
      – PersonEntity:
          Name:
            NameFull: Li Y
      – PersonEntity:
          Name:
            NameFull: Liu Z
      – PersonEntity:
          Name:
            NameFull: Hu S
      – PersonEntity:
          Name:
            NameFull: Ding M
      – PersonEntity:
          Name:
            NameFull: Qin J
      – PersonEntity:
          Name:
            NameFull: Sun H
      – PersonEntity:
          Name:
            NameFull: Pan Y
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 04
              Text: 2026 Apr 22
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2211-3436
          Numbering:
            – Type: volume
              Value: 49
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Cellular oncology (Dordrecht, Netherlands)
              Type: main
ResultId 1